Arash Mowla1, Seyed Ali Dastgheib2, Leila Razeghian Jahromi2. 1. Department of Psychiatry, Substance Abuse and Mental Health Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. mowlaar@gmail.com. 2. Department of Psychiatry, Substance Abuse and Mental Health Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Abstract
BACKGROUND AND OBJECTIVE: Selecting the most effective treatment for major depressive disorder (MDD) is a challenge for clinicians. The aim of this study was to compare the effects of sertraline with duloxetine on major depression signs and symptoms. METHODS: The trial was a 6-week, randomized, controlled, double-blind study. Sixty-three patients with diagnosis of MDD according to DSM-IV-TR criteria were randomly assigned to receive either duloxetine (31 patients) or sertraline (32 patients). The mean dosage of duloxetine was 55 mg/day (range 40-60 mg/day) and the mean dosage of sertraline was 146 mg/day (range 50-200 mg/day). Subjects were assessed at baseline, and at the end of week 6. Depression severity and symptoms were assessed by 21-item Hamilton Depression Rating Scale (HAM-D). RESULTS: Of 63 patients who were randomized to treatment, 54 patients including 28 in the sertraline group and 26 in theduloxetine group completed the trial. The HAM-D total score for both groups was significantly reduced at the end of the trial period without significant difference from each other (p = 0.463). Of the symptoms studied, psychomotor retardation, general somatic symptoms and sexual problems improved more in the duloxetine group. On the other hand, agitation, anxiety symptoms and hypochondriasis ameliorated better in the sertraline group. There was no difference between the two groups regarding the other symptoms. CONCLUSIONS: Our study shows that the antidepressant mechanism of action has influence on its effects on different signs and symptoms. Clinician awareness of an antidepressant's special effects can help in selecting appropriate medicine.
RCT Entities:
BACKGROUND AND OBJECTIVE: Selecting the most effective treatment for major depressive disorder (MDD) is a challenge for clinicians. The aim of this study was to compare the effects of sertraline with duloxetine on major depression signs and symptoms. METHODS: The trial was a 6-week, randomized, controlled, double-blind study. Sixty-three patients with diagnosis of MDD according to DSM-IV-TR criteria were randomly assigned to receive either duloxetine (31 patients) or sertraline (32 patients). The mean dosage of duloxetine was 55 mg/day (range 40-60 mg/day) and the mean dosage of sertraline was 146 mg/day (range 50-200 mg/day). Subjects were assessed at baseline, and at the end of week 6. Depression severity and symptoms were assessed by 21-item Hamilton Depression Rating Scale (HAM-D). RESULTS: Of 63 patients who were randomized to treatment, 54 patients including 28 in the sertraline group and 26 in the duloxetine group completed the trial. The HAM-D total score for both groups was significantly reduced at the end of the trial period without significant difference from each other (p = 0.463). Of the symptoms studied, psychomotor retardation, general somatic symptoms and sexual problems improved more in the duloxetine group. On the other hand, agitation, anxiety symptoms and hypochondriasis ameliorated better in the sertraline group. There was no difference between the two groups regarding the other symptoms. CONCLUSIONS: Our study shows that the antidepressant mechanism of action has influence on its effects on different signs and symptoms. Clinician awareness of an antidepressant's special effects can help in selecting appropriate medicine.
Authors: Hyungjin Myra Kim; Kara Zivin; Hae Mi Choe; Clare M Stano; Dara Ganoczy; Heather Walters; Marcia Valenstein Journal: J Manag Care Spec Pharm Date: 2015-05
Authors: J C Nelson; J S Kennedy; B G Pollock; F Laghrissi-Thode; M Narayan; M S Nobler; D W Robin; I Gergel; J McCafferty; S Roose Journal: Am J Psychiatry Date: 1999-07 Impact factor: 18.112
Authors: Timothy Petersen; Christina Dording; Nicole B Neault; Rebecca Kornbluh; Jonathan E Alpert; Andrew A Nierenberg; Jerrold F Rosenbaum; Maurizio Fava Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2002-01 Impact factor: 5.067
Authors: Andrew A Nierenberg; John H Greist; Craig H Mallinckrodt; Apurva Prakash; Angelo Sambunaris; Gary D Tollefson; Madelaine M Wohlreich Journal: Curr Med Res Opin Date: 2007-02 Impact factor: 2.580
Authors: Daniela Rodrigues-Amorim; José Manuel Olivares; Carlos Spuch; Tania Rivera-Baltanás Journal: Front Psychiatry Date: 2020-10-23 Impact factor: 4.157